Posted by Michael Wonder on 07 Dec 2022
Moleculin granted FDA fast track designation of WP1122 for the treatment of glioblastoma multiforme
7 December 2022 - Moleculin Biotech today announced that the US FDA has granted fast track designation of WP1122 for the treatment of glioblastoma multiforme.
WP1122 was developed as a 2-DG pro-drug to provide a more favourable pharmacological profile and was found to have greater potency than 2-DG alone in pre-clinical models where tumour cells require higher glycolytic activity than normal cells.
